Pharmaforum

23/12/2022

*Which resume format is better, PDF or Word?*
Your resume file format is an important factor to consider when sending your resume for a . Know more about the pros & cons of each format.

*Follow “Make my new resume”* for more such updates.

Make My New Resume | 26 followers on LinkedIn. Helping talent reach its aspirations | Do you know on average a recruiter/HR Manager won't spend >2 minutes looking at each individual job resume? We work extensively in drafting great CVs that can help you grab the job you are aspiring for. A po...

30/08/2021

India's single-day vaccination coverage exceeds 1 crore doses

"India has administered more than 1 crore COVID-19 vaccine doses on Friday. A landmark milestone with highest ever single-day vaccination coverage of over 1 crore doses," said the Ministry of Health and Family Welfare.

Meanwhile, India’s cumulative COVID-19 vaccination coverage crossed 62 crore landmark, while recovery rate currently stood at 97.56 per cent. With the administration of 1,03,35,290vaccine doses in the last 24 hours. The vaccination coverage has surpassed the cumulative figure of 62.29Cr (62,29,89,134). This has been achieved through 67,19,042 sessions.

The ministry further indicate that the sustained and collaborative efforts by the Centre and the States/UTs continue the trend of less than 50,000 daily new cases that is being reported for 62 consecutive days now.
As many as 46,759 new covid cases were reported in the last 24 hours. The active caseload is presently 3,59,775. Active cases presently constitute 1.10% of the country's total positive cases.

"The testing capacity across the country continues to be expanded. The last 24 hours saw a total of 17,61,110tests being conducted. India has so far conducted over 51.68 Cr (51,68,87,602) cumulative tests," the Ministry said.

10/08/2021

Zydus Cadila likely to get emergency use approval for its COVID vaccine this week: Sources.

Ahmedabad-based Zydus Cadila's three-dose COVID-19 vaccine ZyCoV-D is expected to get an emergency-use nod from the expert committee this week, sources said.

Union Health Minister Mansukh Mandaviya last week during the question hour in the Rajya Sabha had said, "The government expects that in October-November, four more Indian pharmaceutical companies will start production of indigenous vaccines that will help to meet the domestic demand, Biological E and Novartis vaccines will also be available in the market in the coming days, while Zydus Cadila will soon get an emergency use nod from Expert Committee."

Zydus Cadila last month had said that it has applied for emergency use authorisation (EUA) with the Indian Drug regulator for its three-dose COVID-19 vaccine ZyCoV-D, and plans to manufacture 10-12 crore doses annually.

The company has conducted the largest clinical trial for its COVID-19 vaccine in India so far in over 50 centers.

The EUA is expected to be given for adults first, though the Drug Controller General of India (DCGI) had earlier asked the Ahmedabad-based firm to return with more data on its ZyCoV-D.

Earlier, during a press briefing, a Member of NITI Aayog Dr V K Paul had said that the DCGI is examining Zydus Cadila's COVID vaccine for children.

"ZuCoV-D is the first-ever plasmid DNA vaccine for human use, it has proven its safety and efficacy profile in our fight against COVID-19," MD of Cadila Healthcare Dr Sharvil Patel said.

30/07/2021

Roche launches spinal muscular atrophy treatment drug in India priced at around Rs 6 lakh per bottle
The drug is approved for the treatment of SMA in adults and children 2 months of age and older, Roche said adding that it was approved by the Indian health authorities after reviewing its efficacy and safety data from three global clinical studies designed to represent a broad spectrum of people living with SMA.

Roche on Thursday said it has launched prescription medicine Evrysdi in India, which is used for treatment of spinal muscular atrophy (SMA) in adults, children aged 2 months and older, at a maximum retail price of around Rs 6 lakh per bottle. Evrysdi was first approved by the United States Food and Drug Administration (US FDA) in August 2020 and is now available in India within 11 months of the US approval. Since its launch, over 4,000 SMA patients across over 50 countries have benefitted from the drug, Roche said in a statement.

Evrysdi is administered daily at home orally and is designed to treat spinal muscular atrophy by increasing production of the survival motor neuron (SMN) protein, it added.

22/07/2021

Part 1 of insight seen from Pharma sales professionals opinion survey. I hope everyone will relate with it.

22/07/2021

KEM Hospital Mumbai dean Dr Hemant Deshmukh gets US patent for ‘stent’ that aids weight loss.

Can a device control blood flow in such a way that one loses weight?

The head of one of the country’s most prestigious medical schools, KEM Hospital in Parel, recently earned a patent for such a concept from the US Patent Office. Dean Dr Hemant Deshmukh, an interventional radiologist, thought of the device while fixing narrowed blood vessels around the small intestine.

Cardiologists fix narrowed vessels around the heart and interventional radiologists are trained to similarly fix vessels in other body parts such as the brain, lungs, legs and the abdomen, among others, to prevent strokes and gangrene. “The self-expanding, blood-flow resisting device we have devised is about an idea taking shape,” Dr Deshmukh, who has performed thousands of interventional procedures. said.

08/07/2021

Glenmark Pharmaceuticals will be conducting a Phase III trial on a nitric oxide nasal spray, which it claims is effective in treatment of Covid-19.

The company had sought emergency approval for import and marketing of the nasal spray from the drug regulator last week. However, the subject expert Committee (SEC) under the drug regulator recommended Glenmark to conduct the Phase III trial.

Glenmark has joined hands with the Canadian company named Sanotize.

06/07/2021

Tit for tat:

In a diplomatic retaliatory move against vaccine nationalism, India has said it would recognise EU’s digital Covid certificate on a reciprocal basis and would not accept it until EU does the same for Indian vaccines— Covishield and Covaxin. The EU “Green Pass” is expected to come into effect from July 1.

“We have conveyed to EU member-states that India will institute a reciprocal policy for recognition of the EU digital Covid certificate. Upon notification of Covishield and Covaxin for inclusion in the EU digital Covid certificate and recognition of Indian Co-Win vaccination certificates, Indian health authorities would reciprocally exempt the EU member-state concerned for exemption from mandatory quarantine of all those persons carrying the EU Covid certificate,” said a source.

The EU digital Covid certificate, known as “Green Pass” will exempt those whose are double vaccinated with vaccines accepted by the EU from mandatory quarantine. The European Union’s ‘vaccine passport’ programme has approved only four vaccines— Vaxzevria (Oxford-AstraZeneca), Comirnaty (Pfizer-BioNTech), Spikevax (Moderna) and Janssen-Johnson & Johnson. Covishield is exactly the same as Vaxzevria, but failed to make the cut. Covaxin has not been considered, largely because it is yet to get a WHO approval.

06/07/2021

Sun Pharma is recalling 50,868 bottles of diabetes drug (Metformin HCl extended-release tablets) in the US market, according to the US Food and Drug Administration (USFDA).

The US-based arm of the drug firm is recalling the affected lot of 500 mg tablets (in 500 count bottles) due to "presence of foreign substance identified as activated carbon", as per the latest Enforcement Report issued by the US health regulator.

The tablets were produced at drug major's Halol (Gujarat) based manufacturing plant and later distributed in the US by Cranbury (NJ) based Sun Pharmaceutical Industries, Inc. The USFDA has classified the voluntary recall undertaken by the drugmaker as class II recall.

30/04/2021

23/04/2021

Tocilizumab Injection FAILED IN Phase 3 trial for COVID conducted by their inventor Roche in both primary as well as secondary endpoints, no improvement in clinical status & not any single mortality benefits have been seen in CT after taking this injection.

This is the drug with INR 40,000 MRP in india, selling in black market at around 100,000 Rs. People thought it will work perfectly due to its high cost.. Many people might have died due to serious side effects (liver kidney damage, intense immunosuppression) of this drug.

Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 associated pneumonia COVACTA trial did not meet its primary endpoint of improved clinical status in patients with COVID-19 associated pneumonia, or the key secondary endpoint of...